Further analysis in a larger cohort of lung cancer patients confirmed that Orai3 is overexpressed in tumoral samples as compared to adjacent non-tumoral tissue but revealed that the expression of Orai3 does not correlate with EGF receptor mutation, KRAS mutation, or the TNM stage (classification of malignant tumors based on the size, lymph nodes involved and metastasis) [50]. This evidence concerns the gene ORAI3 and lung carcinoma.